AFP阴性肝癌的肿瘤标志物诊断的研究进展

2024-06-30 07:34| 来源: 网络整理| 查看: 265

文献综述 Open Access Copyright ©The Author(s) 2011. Published by Baishideng Publishing Group Inc. All rights reserved. 世界华人消化杂志. 2011-11-28; 19(33): 3420-3425 在线出版日期: 2011-11-28. doi: 10.11569/wcjd.v19.i33.3420 AFP阴性肝癌的肿瘤标志物诊断的研究进展王婷, 张焜和 王婷, 张焜和, 南昌大学第一附属医院消化内科江西省消化疾病重点实验室江西省南昌市 330006 ORCID number: $[AuthorORCIDs] 基金项目: 国家自然科学基金资助项目, No. 81060197;江西省自然科学基金资助项目, No. 2010GZY0318.作者贡献分布: 本综述由王婷完成初稿; 张焜和审校修改. 通讯作者: 张焜和, 教授, 主任医师, 330006, 江西省南昌市永外正街17号, 南昌大学第一附属医院消化内科, 江西省消化疾病研究所. [email protected] 收稿日期: 2011-08-28修回日期: 2011-10-30接受日期: 2011-11-04在线出版日期: 2011-11-28

甲胎蛋白(alpha-fetoprotein, AFP)是肝细胞癌(hepatocellular carcinoma, HCC)的主要标志物, 测定血清AFP水平是目前诊断HCC的主要手段. 约1/3的HCC患者血清AFP水平正常, 即所谓的AFP阴性肝癌, 这部分患者的诊断是目前肝癌诊断中需解决的关键问题. 多年来, 人们一直在寻找能弥补AFP不足的肝癌标志物, 以提高HCC的诊断水平. 本文综述了有关AFP阴性肝癌的肿瘤标志物诊断研究进展, 主要内容包括传统肝癌标志物对AFP阴性肝癌的诊断价值, 新肝癌标志物对AFP阴性肝癌的诊断价值, 以及对AFP阴性HCC具有潜在诊断价值的生物标志物.

关键词: 甲胎蛋白; 肝细胞癌; 肿瘤标志物; 诊断 引文著录: 王婷, 张焜和. AFP阴性肝癌的肿瘤标志物诊断的研究进展. 世界华人消化杂志 2011; 19(33): 3420-3425 Progress in research of tumor markers for diagnosis of hepatocellular carcinoma in AFP-negative patients Ting Wang, Kun-He Zhang Ting Wang, Kun-He Zhang, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University; Jiangxi Provincial Key Laboratory for Digestive Diseases, Nanchang 330006, Jiangxi Province, China Supported by: National Natural Science Foundation of China, No. 81060197; the Jiangxi Provincial Natural Science Foundation, No. 2010GZY0318.Correspondence to: Kun-He Zhang, Professor, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, 17 Yongwai Zheng Street, Nanchang 330006, Jiangxi Province, China. [email protected] Received: August 28, 2011Revised: October 30, 2011Accepted: November 4, 2011Published online: November 28, 2011

Alpha-fetoprotein (AFP) is an important marker for hepatocellular carcinoma (HCC), and the detection of serum AFP is currently the principal method for the diagnosis of HCC. About on-e-third of HCC patients have normal serum AFP concentration, and the diagnosis of HCC in these patients is challenging. In recent years, many studies have been done to seek other tumor markers for HCC. In this paper, we review the recent progress in research of tumor markers for the diagnosis of HCC in AFP-negative patients.

Key Words: Alpha-fetoprotein; Hepatocellular carcinoma; Tumor markers; Diagnosis Citation: Wang T, Zhang KH. Progress in research of tumor markers for diagnosis of hepatocellular carcinoma in AFP-negative patients. Shijie Huaren Xiaohua Zazhi 2011; 19(33): 3420-3425 URL: https://www.wjgnet.com/1009-3079/full/v19/i33/3420.htm DOI: https://dx.doi.org/10.11569/wcjd.v19.i33.3420 0 引言

肝细胞癌(hepatocellular carcinoma, HCC)的发病率在世界范围内位列第5, 在我国位列第3, 且呈逐年上升趋势[1,2]. HCC的5年生存率不足5%, 早期诊断及手术治疗仍是目前改善患者预后最有效的方法. 甲胎蛋白(alpha-fetoprotein, AFP)是目前临床上最主要、应用最广泛的HCC早期筛查血清标志物, 但因其在转录水平上受多种因素调控, 使部分HCC患者血清AFP水平正常(5 cm的肝癌阳性率为79.31%,

【本文地址】

公司简介

联系我们